Stay on top of the latest research and practice
Don't miss a unique opportunity to interact with well-known experts while enjoying breakfast at the start of the day.
Check out the list of topics and experts below, and enroll for a topic of your choice as you register for ESGO 2022.
Get a head start and Register Now!
Imperial College London, United Kingdom
In this teaching session we will explore the possibilities and opportunities arising from the promising new world of radiomics technology. We will discuss how artificial intelligence can help us improve the outcome of patients with gynaecological cancers and how we can already now implement it into clinical practice.
UCL Cancer Institute, United Kingdom
Finding head space and time for non-clinical activities in a busy clinical practice can be challenging. There are many routes to making a national and international impact, but above all, it requires setting goals, determination, and ‘networking’. I will briefly discuss my own journey over 25 years where my focus has been on clinical trials leadership and input into national and international peer groups and decision-making bodies. Understanding the national and international frameworks is a helpful guide to the pathways that are available, particularly if the passage is self-directed and if formal mentorship is not available. Tips on how to start on the ‘road to clinical trials’ will be given as well as suggestions to take opportunities to develop a leadership profile nationally and internationally.
US Oncology Research, TX, United States
Hypothesis generation and hypothesis testing are the cornerstones of clinical research. Carefully crafted hypotheses accompanied by successful hypothesis testing has brought an unprecedented environment for new drug and device approvals. However, understanding of commonly used statistical tools to evaluate clinical endpoints is variable and misinterpretation of clinical trial results can lead to unintended consequences in patients when treatment decisions are made. In this session we will have a robust discussion of trial designs used in contemporary phase I through IV clinical trials, commonly used endpoints, how these endpoints are used to support regulatory agency decisions, and how interpretation may be misconstrued from reported outcomes.
Klinik für Gynäkologie & Gynäkologischer Onkologie, Ev. Kliniken Essen-Mitte, Germany
The speaker will describe the role and its impact on the prognosis of cytoreductive surgery for relapsed ovarian cancer.
The speaker and participants will discuss the selection process for identifying potential candidates for secondary cytoreductive surgery.
Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Italy
The interest in HIPEC and advanced ovarian cancer is increasing, despite the fact that provided data on its survival outcomes and safety are still not universally accepted and are a matter of debate among experts. Within this topic there is room to discuss the pros and cons of HIPEC treatment in relation to available data and its future perspectives also in light of the development of precision medicine in advanced ovarian cancer.
Memorial Sloan Kettering Cancer Center, NY, United States
The focus of this lecture is to describe the indications and techniques for pelvic exenteration surgical approaches for vulvar cancer. The lecture will cover the technical aspects of pelvic exenteration cancer surgery to address resection of persistent and recurrent disease and reconstruction techniques. Technical aspects, anatomy landmarks, tips and tricks will be provided. The lectures will also cover plastic techniques including local flaps and myocutaneous flaps.
Pedro T. Ramirez
MD Anderson Cancer Center Houston, TX, United States
Data will be presented on the final analysis of the LACC trial evaluating disease-free and overall survival with all patients completing follow-up at median of 4.5 years. In addition, exploratory analysis results will be discussed which include the stratification by tumour size (<2cm vs. >2cms), outcomes based on residual disease, impact of prior conisation, and rates of carcinomatosis at recurrence.
The topic of long-term survivors is a new and so far neglected theme in the clinical and scientific community.
Currently, new guidelines for the programmes of long-term follow-up for survivors from gynaecologic cancer are under development.
Based on several studies, more than every second survivor with gynaecological malignancy still experienced health concerns/long-term side effects including neurologic symptoms, sleep disturbance, fatigue, sexual dysfunction, bowel and urinary problems, and lymphoedema. The meet-the expert session will share experience of the structure and the programs of a large interdisciplinary and interprofessional cancer survivorship clinic and provide insights of recent scientific projects.
Anil K. Sood
MD Anderson Cancer Center, TX, United States
Creating successful bridges between laboratory/discovery science and clinical practice is essential for successful translation. In this session, we will cover wide-ranging topics in implementing translational research in the clinic.
Not yet an ESGO member?
Join or renew today
Any Questions? Check out the Frequently Asked Questions Section!
Get notified on all news and activities right in your mailbox.
Find out More
Scientific Programme & iPlanner
Explore it Now!
Great moments from ESGO 2021!
View it Now!